COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?

doi:10.1007/s00204-020-02734-1

Editorial

. 2020 Apr;94(4):1367-1369.

doi: 10.1007/s00204-020-02734-1. Epub 2020 Apr 8.

COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?

Joost Boeckmans¹, Robim M Rodrigues¹, Thomas Demuyser², Denis Piérard², Tamara Vanhaecke¹, Vera Rogiers³

Affiliations

¹ Department of In Vitro Toxicology and Dermato-Cosmetology (IVTD), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.
² Department of Microbiology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium.
³ Department of In Vitro Toxicology and Dermato-Cosmetology (IVTD), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. vera.rogiers@vub.be.

PMID: 32266419
PMCID: PMC7138655
DOI: 10.1007/s00204-020-02734-1

Editorial

COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?

Joost Boeckmans et al. Arch Toxicol. 2020 Apr.

. 2020 Apr;94(4):1367-1369.

doi: 10.1007/s00204-020-02734-1. Epub 2020 Apr 8.

Authors

Joost Boeckmans¹, Robim M Rodrigues¹, Thomas Demuyser², Denis Piérard², Tamara Vanhaecke¹, Vera Rogiers³

Affiliations

¹ Department of In Vitro Toxicology and Dermato-Cosmetology (IVTD), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.
² Department of Microbiology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium.
³ Department of In Vitro Toxicology and Dermato-Cosmetology (IVTD), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. vera.rogiers@vub.be.

PMID: 32266419
PMCID: PMC7138655
DOI: 10.1007/s00204-020-02734-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Cited by

Remarkable gastrointestinal and liver manifestations of COVID-19: A clinical and radiologic overview.
Fang LG, Zhou Q. Fang LG, et al. World J Clin Cases. 2021 Jul 6;9(19):4969-4979. doi: 10.12998/wjcc.v9.i19.4969. World J Clin Cases. 2021. PMID: 34307547 Free PMC article. Review.
Liver Damage and COVID-19: At Least a "Two-Hit" Story in Systematic Review.
Montori M, Baroni GS, Santori P, Di Giampaolo C, Ponziani F, Abenavoli L, Scarpellini E. Montori M, et al. Curr Issues Mol Biol. 2023 Apr 4;45(4):3035-3047. doi: 10.3390/cimb45040199. Curr Issues Mol Biol. 2023. PMID: 37185723 Free PMC article. Review.
COVID-19-Associated Liver Injury.
Gildea DT, Woo SM, O'Connor CE, Rangnekar AS. Gildea DT, et al. Hepat Med. 2023 Feb 21;15:1-9. doi: 10.2147/HMER.S384108. eCollection 2023. Hepat Med. 2023. PMID: 36852138 Free PMC article. Review.
Liver injury in COVID-19: A minireview.
Hu WS, Jiang FY, Shu W, Zhao R, Cao JM, Wang DP. Hu WS, et al. World J Gastroenterol. 2022 Dec 21;28(47):6716-6731. doi: 10.3748/wjg.v28.i47.6716. World J Gastroenterol. 2022. PMID: 36620342 Free PMC article. Review.
Implications of metabolic dysfunction associated fatty liver disease in COVID-19.
Chakraborty R, Sharma D, Kapoor DU, Dwivedi A, Khabiya R, Sen S. Chakraborty R, et al. World J Clin Cases. 2023 Feb 26;11(6):1275-1286. doi: 10.12998/wjcc.v11.i6.1275. World J Clin Cases. 2023. PMID: 36926128 Free PMC article. Review.

See all "Cited by" articles

References

1. Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. Am J Pathol. 2006;168:1057–1059. doi: 10.2353/ajpath.2006.051296. - DOI - PMC - PubMed
1. Boeckmans J, Natale A, Buyl K, et al. Human-based systems: mechanistic NASH modelling just around the corner? Pharmacol Res. 2018;134:257–267. doi: 10.1016/j.phrs.2018.06.029. - DOI - PubMed
1. Boeckmans J, Buyl K, Natale A, et al. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. Pharmacol Res. 2019;144:377–389. doi: 10.1016/j.phrs.2019.04.016. - DOI - PubMed
1. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis. 2004;38:104–108. doi: 10.1086/381453. - DOI - PubMed
1. Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-NCoV infection. bioRxiv. 2020 doi: 10.1101/2020.02.03.931766. - DOI

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. Am J Pathol. 2006;168:1057–1059. doi: 10.2353/ajpath.2006.051296. - DOI - PMC - PubMed

[2] Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. Am J Pathol. 2006;168:1057–1059. doi: 10.2353/ajpath.2006.051296. - DOI - PMC - PubMed

[3] Boeckmans J, Natale A, Buyl K, et al. Human-based systems: mechanistic NASH modelling just around the corner? Pharmacol Res. 2018;134:257–267. doi: 10.1016/j.phrs.2018.06.029. - DOI - PubMed

[4] Boeckmans J, Natale A, Buyl K, et al. Human-based systems: mechanistic NASH modelling just around the corner? Pharmacol Res. 2018;134:257–267. doi: 10.1016/j.phrs.2018.06.029. - DOI - PubMed

[5] Boeckmans J, Buyl K, Natale A, et al. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. Pharmacol Res. 2019;144:377–389. doi: 10.1016/j.phrs.2019.04.016. - DOI - PubMed

[6] Boeckmans J, Buyl K, Natale A, et al. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. Pharmacol Res. 2019;144:377–389. doi: 10.1016/j.phrs.2019.04.016. - DOI - PubMed

[7] Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis. 2004;38:104–108. doi: 10.1086/381453. - DOI - PubMed

[8] Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis. 2004;38:104–108. doi: 10.1086/381453. - DOI - PubMed

[9] Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-NCoV infection. bioRxiv. 2020 doi: 10.1101/2020.02.03.931766. - DOI

[10] Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-NCoV infection. bioRxiv. 2020 doi: 10.1101/2020.02.03.931766. - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?

Affiliations

COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical